What role can bispecific antibodies play in cancer targeting? A hypothesis.
Monoclonal antibodies (mAbs) are currently among the best remedies in the treatment of cancer disorders. Almost 12 anti-cancer therapeutic mAbs have been approved for clinical applications. Although mAbs have been found to target specific antigens, numerous impediments are emerged in cancer therapy by mAbs because of expression of a low level of the same antigens on the surface of normal cells. To exterminate tumor cells specifically, the current paper puts forward a novel strategy to target cancer cells more selectively by bispecific monoclonal antibody (bsmAb), which has an affinity against the tumor-specific antigens. Translocations in genes and chromosomes are known triggers for the development of human cancers. The mutations in gene profile could create novel tumor-specific proteins and receptors which could be detected using bsmAbs.